CESSATION THERAPEUTICS, LLC
Development of the anti-fentanyl monoclonal antibody, CSX-1004, for prophylaxis against fentanyl and fentanyl analog overdose
Development of the anti-fentanyl monoclonal antibody, CSX-1004, for prophylaxis against fentanyl and fentanyl analog overdose is a funding opportunity from CESSATION THERAPEUTICS, LLC, up to 2612736, closing July 31, 2028.
Jul 31, 2028
(731d left)Overview
The opioid crisis in the United States has been dominated by illicitly manufactured fentanyl for a majority of the last decade, during which time over 400,000 Americans have died from unintentional overdose due to fentanyl or fentanyl analogs. The overdose reversal agent, naloxone, has been the cornerstone of opioid…